Neuraxpharm attends 27th European Congress of Psychiatry

  • Attendance at key European psychiatry summit underlines commitment to medical community
  • CEO Dr. Jörg-Thomas Dierks to attend psychiatry Congress being held in Warsaw

April 5, 2019

Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces it will be attending the EPA 2019 Congress (27th European Congress of Psychiatry) from 6th – 9th April 2019 at the Expo XXI in Warsaw, Poland. Dr. Jörg-Thomas Dierks, CEO and members of the Neuraxpharm team will attend the Congress and host meetings.

Following the recent rebranding in 2018, Neuraxpharm is building on its expertise and vision as a true pan-European CNS focused specialty pharmaceutical company. Neuraxpharm is also able to bring its in-depth knowledge of the various markets where it has operated for more than 30 years as a reliable partner for healthcare professionals.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH